Latest Content

Study finds how multiple myeloma cells adapt to immunotherapy, helping explain why patients relapse and guiding personalized treatment approaches.

The NexTGen team launches the world's largest CAR-T cell trial for pediatric solid tumors, offering new hope for children with relapsed cancer.

Darlifarnib plus Cabometyx showed tumor responses in resistant kidney cancer following prior treatment.

An expert discusses the need to tailor treatment duration in bladder cancer, balancing improved outcomes with toxicity and exploring new tools.

Tamera Anderson-Hanna reflects on survivorship, redefining life with family, travel, purpose and giving back while embracing time as a precious guide.

Patients with cancer have a new generic option for methotrexate injection following FDA approval of a therapeutic equivalent for multiple conditions.

The FDA accepted an investigational new drug application for chemo-related neuropathy, advancing a potential non-opioid treatment into a clinical trial.

The OPTIMAL trial finds oral DHP107 is as effective as IV paclitaxel for patients with advanced breast cancer while reducing side effects like neuropathy.

Elraglusib plus chemotherapy doubled one-year survival in metastatic pancreatic cancer, showing improved outcomes in a phase 2 trial.

Before my daughter was diagnosed with breast cancer, the “M” word was not a part of my vocabulary.

PDS01ADC showed high response rates in metastatic colorectal cancer in a phase 2 trial after prior treatment.

After an aggressive breast cancer diagnosis, psychologist Loraine Alderman retires to bridge gaps in patient literature through powerful advocacy.

Dr. Sandy Srinivas explains how age, comorbidities and medications influence personalized prostate cancer treatment decisions.